Reveal Biosciences Names Jamil Hussain as Chief Commercial & Strategy Officer

San Diego, US, Dec. 16, 2020 –  Reveal Biosciences today announced that it has named Jamil Hussain as Chief Commercial & Strategy Officer.  

Jamil brings over 26 years of life sciences and healthcare leadership, with significant experience in startups and corporate businesses including Pfizer, AstraZeneca, Microstrategy, Oracle, Deloitte, EY and more recently serving with IQVIA. He has a strong focus on technology, data, and SaaS within digital pathology and life sciences companies globally. 

The search committee conducted a comprehensive evaluation of a wide range of candidates to identify the right commercial leader at this time of rapid growth.  “We considered many outstanding executives and concluded that Jamil was the best compliment to our executive leadership team and vision for the future.  His knowledge of the SaaS landscape and Artificial Intelligence (AI) within life sciences and digital pathology is outstanding and will strengthen Reveal’s position as an industry leader in AI data powered pathology.” said Claire Weston, PhD, CEO.  “I am excited to join the executive leadership team at Reveal,” said Jamil Hussain. “Reveal has served with a single vision to provide the support, tools, and technology to improve research and patient outcomes, paving new frontiers in AI empowered digital pathology. I am honored to be part of a team which will continue to make this difference through industry partnerships.”  

About Reveal Biosciences

Reveal Biosciences is creating a new generation of data powered pathology to enhance research and improve global healthcare. Reveal combines cutting edge artificial intelligence (AI) with traditional histopathology to transform tissue biology into actionable data driven Pathology Intelligence. The imageDx data-powered pathology platform provides secure whole slide image management and AI-based image processing in the cloud. Reveal’s fully automated laboratory and experienced scientists also provide histopathology, immunohistochemistry (IHC) and in situ hybridization (ISH) expertise for a wide range of pharmaceutical, biotech, academic, and government institutions.   With a world class team of data and research scientists focused on addressing some of the biggest problems in healthcare, Reveal has developed a pipeline of AI-based digital assays for preclinical research, clinical trials, and decision support. 

Pathology Revealed

Subscribe to our  newsletter to receive updates, access digital pathology resources, and more.